The other thing potentially going for it is Trump's policy to bring manufacturing back to the U.S as supposingly 85%(?) of generics are manufactured in the subcontinent. If push comes to shove with Trump MYX manufacturing facilities will be well placed to be leveraged from overseas small - medium pharmas for contract services.
It's also a balanced business where three of four segments are growing circa 10% Specialty explosive growth at 100%. Company is horribly mispriced on current and known information, yes it can be even more mispriced but we are investing in the tomorrow not the yesterday nor today.
There is active consolidation in the generics sector huge opportunity for MYX to get into high profile partnerships and even merger.
Razzle Dazzle us Mr Scott Richards.
-
- There are more pages in this discussion • 166 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.07 |
Change
0.050(1.00%) |
Mkt cap ! $411.9M | |||
| Open | High | Low | Value | Volume |
| $5.00 | $5.14 | $4.94 | $712.4K | 141.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1059 | $5.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.13 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2025 (20 minute delay) ? |
| MYX (ASX) Chart |